DADC
VTGN icon

D.A. Davidson & Co’s VistaGen Therapeutics VTGN Stock Holding History

D.A. Davidson & Co’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,217
Closed -$8.29K – 1424
2023
Q1 		$8.29K Hold
2,217
– – ﹤0.01% 1330
2022
Q4 		$6.85K Hold
2,217
– – ﹤0.01% 1309
2022
Q3 		$10K Sell
2,217
-1,583
-42% -$15.7K ﹤0.01% 1277
2022
Q2 		$100K Sell
3,800
-450
-11% -$15.9K ﹤0.01% 1224
2022
Q1 		$158K Hold
4,250
– – ﹤0.01% 1231
2021
Q4 		$249K Hold
4,250
– – ﹤0.01% 1115
2021
Q3 		$349K Sell
4,250
-133
-3% -$11.6K ﹤0.01% 951
2021
Q2 		$414K Sell
4,383
-67
-2% -$4.96K ﹤0.01% 886
2021
Q1 		$284K Sell
4,450
-133
-3% -$8.88K ﹤0.01% 972
2020
Q4 		$267K Hold
4,583
– – ﹤0.01% 883
2020
Q3 		$96K Sell
4,583
-884
-16% -$18.3K ﹤0.01% 923
2020
Q2 		$86K Buy
5,467
+1,800
+49% +$24.6K ﹤0.01% 910
2020
Q1 		$48K Hold
3,667
– – ﹤0.01% 965
2019
Q4 		$76K Buy
3,667
+167
+5% +$4.22K ﹤0.01% 988
2019
Q3 		$112K Buy
3,500
+750
+27% +$16.7K ﹤0.01% 959
2019
Q2 		$60K Sell
2,750
-1,067
-28% -$28.3K ﹤0.01% 977
2019
Q1 		$147K Buy
3,817
+684
+22% +$29.8K ﹤0.01% 1066
2018
Q4 		$141K Buy
3,133
+583
+23% +$31.8K ﹤0.01% 1019
2018
Q3 		$111K Hold
2,550
– – ﹤0.01% 1129
2018
Q2 		$105K Buy
2,550
+767
+43% +$26.7K ﹤0.01% 1084
2018
Q1 		$50K Sell
1,783
-1,500
-46% -$55.7K ﹤0.01% 1091
2017
Q4 		$109K Hold
3,283
– – ﹤0.01% 1074
2017
Q3 		$157K Hold
3,283
– – ﹤0.01% 1043
2017
Q2 		$184K Buy
3,283
+250
+8% +$14.6K ﹤0.01% 997
2017
Q1 		$178K Buy
3,033
+133
+5% +$10.8K ﹤0.01% 990
2016
Q4 		$324K Buy
2,900
+1,900
+190% +$221K 0.01% 814
2016
Q3 		$126K Buy
+1,000
New +$109K ﹤0.01% 1144

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.A. Davidson & Co's VTGN Position: Q2 2023 in Review

D.A. Davidson & Co sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 2,217 shares — an estimated $8.29K sold.

D.A. Davidson & Co first reported a position in VTGN in Q3 2016 and held it in 27 quarters. The position peaked at $414K in Q2 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • D.A. Davidson & Co reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • D.A. Davidson & Co sold 2,217 VistaGen Therapeutics shares in Q2 2023, an estimated $8.29K.
  • D.A. Davidson & Co first reported a position in VistaGen Therapeutics in Q3 2016 and held it in 27 quarters.
  • D.A. Davidson & Co's VistaGen Therapeutics position peaked at $414K in Q2 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on D.A. Davidson & Co's 13F filing for Q2 2023, filed 11 Aug 2023.